These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 3288815)

  • 1. The Ha-ras polymorphism in myelodysplasia and acute myeloid leukaemia.
    Carter G; Worwood M; Jacobs A
    Leuk Res; 1988; 12(5):385-91. PubMed ID: 3288815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymerase chain reaction analysis of allele frequency and loss at the Harvey ras locus in myeloid malignancies.
    Ardern JC; Saunders MJ; Hyde K; Lawson R; Yin JA; Lucas GS
    Leukemia; 1993 Feb; 7(2):258-62. PubMed ID: 8426479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Familial myelodysplasia and acute myeloid leukaemia--a review.
    Owen C; Barnett M; Fitzgibbon J
    Br J Haematol; 2008 Jan; 140(2):123-32. PubMed ID: 18173751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ha-ras hypervariable alleles in myelodysplasia.
    Thein SL; Oscier DG; Flint J; Wainscoat JS
    Nature; 1986 May 1-7; 321(6065):84-5. PubMed ID: 3010134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of N-ras mutations in children with myelodysplastic syndromes and acute myeloid leukemia.
    Lübbert M; Mirro J; Kitchingman G; McCormick F; Mertelsmann R; Herrmann F; Koeffler HP
    Oncogene; 1992 Feb; 7(2):263-8. PubMed ID: 1549347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic variants involved in oxidative stress, base excision repair, DNA methylation, and folate metabolism pathways influence myeloid neoplasias susceptibility and prognosis.
    Gonçalves AC; Alves R; Baldeiras I; Cortesão E; Carda JP; Branco CC; Oliveiros B; Loureiro L; Pereira A; Nascimento Costa JM; Sarmento-Ribeiro AB; Mota-Vieira L
    Mol Carcinog; 2017 Jan; 56(1):130-148. PubMed ID: 26950655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia.
    Vasioukhin V; Anker P; Maurice P; Lyautey J; Lederrey C; Stroun M
    Br J Haematol; 1994 Apr; 86(4):774-9. PubMed ID: 7918071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical and genetic background of familial myelodysplasia and acute myeloid leukemia].
    Király PA; Kállay K; Marosvári D; Benyó G; Szőke A; Csomor J; Bödör C
    Orv Hetil; 2016 Feb; 157(8):283-9. PubMed ID: 26876264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetics of therapy-related myelodysplasia and acute myeloid leukemia.
    Pedersen-Bjergaard J; Andersen MK; Andersen MT; Christiansen DH
    Leukemia; 2008 Feb; 22(2):240-8. PubMed ID: 18200041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple point mutation of N-ras and K-ras oncogenes in myelodysplastic syndrome and acute myelogenous leukemia.
    Nakagawa T; Saitoh S; Imoto S; Itoh M; Tsutsumi M; Hikiji K; Nakamura H; Matozaki S; Ogawa R; Nakao Y
    Oncology; 1992; 49(2):114-22. PubMed ID: 1574246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations.
    Niimi H; Harada H; Harada Y; Ding Y; Imagawa J; Inaba T; Kyo T; Kimura A
    Leukemia; 2006 Apr; 20(4):635-44. PubMed ID: 16467864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The non-random distribution of point mutations in leukaemia and myelodysplasia--a possible pointer to their aetiology.
    Parry TE
    Leuk Res; 1997 Jun; 21(6):559-74. PubMed ID: 9279367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia.
    Braun T; Fenaux P
    Br J Haematol; 2008 May; 141(5):576-86. PubMed ID: 18410457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP2B6 gene single nucleotide polymorphisms and leukemia susceptibility.
    Yuan ZH; Liu Q; Zhang Y; Liu HX; Zhao J; Zhu P
    Ann Hematol; 2011 Mar; 90(3):293-9. PubMed ID: 20878158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Marked genetic heterogeneity in familial myelodysplasia/acute myeloid leukaemia.
    Holme H; Hossain U; Kirwan M; Walne A; Vulliamy T; Dokal I
    Br J Haematol; 2012 Jul; 158(2):242-248. PubMed ID: 22533337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute Myeloid Leukemia With Myelodysplasia-Related Changes.
    Vardiman J; Reichard K
    Am J Clin Pathol; 2015 Jul; 144(1):29-43. PubMed ID: 26071460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clonality studies and N-ras and p53 mutation analysis of hematopoietic cells in Fanconi anemia.
    Venkatraj VS; Gaidano G; Auerbach AD
    Leukemia; 1994 Aug; 8(8):1354-8. PubMed ID: 8057673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes.
    Badar T; Patel KP; Thompson PA; DiNardo C; Takahashi K; Cabrero M; Borthakur G; Cortes J; Konopleva M; Kadia T; Bohannan Z; Pierce S; Jabbour EJ; Ravandi F; Daver N; Luthra R; Kantarjian H; Garcia-Manero G
    Leuk Res; 2015 Dec; 39(12):1367-74. PubMed ID: 26547258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clonal evolutions during long-term cultures of bone marrow from de novo acute myeloid leukaemia with trilineage myelodysplasia and with myelodysplastic remission marrow.
    Tamura S; Kanamaru A; Takemoto Y; Kakishita E; Nagai K
    Br J Haematol; 1993 Jun; 84(2):219-26. PubMed ID: 8398821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. t(8;21) myelodysplasia, an early presentation of M2 AML.
    Taj AS; Ross FM; Vickers M; Choudhury DN; Harvey JF; Barber JC; Barton C; Smith AG
    Br J Haematol; 1995 Apr; 89(4):890-2. PubMed ID: 7772527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.